-
公开(公告)号：US20230183769A1
公开(公告)日：2023-06-15
申请号：US17893742
申请日：2022-08-23
Applicant: BioNTech SE
Inventor： Irena Rabe , Maximilian Buff , Thomas Ziegenhals , Johanna Drögemüller , Andreas Kuhn , Stephanie Fesser , Rodney Gene Combs , Nicole Eschmann , Jennifer Ann Schoborg Romine , Jenna Kathryn Williamson
CPC classification number: C12P19/34 , C12N9/1247
Abstract: The present disclosure provides technologies for in vitro transcription reactions, particularly for production of pharmaceutical grade RNA, and in some embodiments for large scale production.
-
公开(公告)号：US11673939B2
公开(公告)日：2023-06-13
申请号：US16972794
申请日：2019-06-06
Applicant: BioNTech SE
Inventor： Ugur Sahin , Bonny Gaby Lui , Nadja Salomon , Joycelyn Wüstehube-Lausch , Matin Daneschdar , Hans-Ulrich Schmoldt , Markus Fiedler
IPC: C07K14/78 , C07K1/107 , G01N33/574 , G01N33/68 , A61K38/00
CPC classification number: C07K14/78 , C07K1/1075 , G01N33/574 , G01N33/68 , A61K38/00
Abstract: The present invention relates to the diagnosis and treatment of diseases expressing Fibronectin Extra Domain B (EDB) such as diseases characterized by tissue remodeling and/or angiogenesis, in particular cancerous diseases, such as head and neck, brain, colorectal, lung, prostate and breast cancer. More particularly, the invention concerns peptides targeting Fibronectin Extra Domain B.
-
公开(公告)号：US20230145774A1
公开(公告)日：2023-05-11
申请号：US17907013
申请日：2021-03-30
Applicant: BIONTECH SE , TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
Inventor： Ugur SAHIN , Lena Mareen KRANZ , Mustafa DIKEN , Lina HILSCHER , Sebastian KREITER
CPC classification number: A61K39/0011 , A61K39/39 , A61P37/02 , A61K2039/55561 , A61K2039/55538 , A61K2039/55527 , A61K2039/55522
Abstract: The present disclosure relates to methods and agents for antigen vaccination and inducing effective antigen-specific immune effector cell responses such as T cell responses. Specifically, the present disclosure relates to methods comprising administering to a subject (i) non-immunogenic RNA encoding a peptide or protein comprising an epitope for inducing an immune response against an antigen in the subject, i.e., non-immunogenic RNA encoding vaccine antigen; and (ii) an immunostimulant or RNA encoding an immunostimulant. Administering to the subject non-immunogenic RNA encoding vaccine antigen may provide (following expression of the RNA by appropriate target cells) vaccine antigen for stimulation, priming and/or expansion of immune effector cells and, thus, may induce an immune response against vaccine antigen (and disease-associated antigen) in the subject.
-
公开(公告)号：US20230099898A1
公开(公告)日：2023-03-30
申请号：US17904937
申请日：2021-02-26
Applicant: BioNTech SE , Johannes Gutenberg-Universitat Mainz
Inventor： Heinrich HAAS , Sara NOGUEIRA , Peter LANGGUTH , Christian SIEWERT , Vera CORNET
IPC: A61K9/16 , C12N15/88 , A61K31/7105
Abstract: The present disclosure relates to RNA particles for delivery of RNA to target tissues after administration, in particular after parenteral administration such as intramuscular, intravenous, subcutaneous or intratumoral administration, and compositions comprising such RNA particles. The present disclosure, in particular, relates to RNA particles comprising RNA, at least one cationic or cationically ionizable lipid or lipid-like material, and at least one cationic polymer, wherein the particles do not have a core-shell structure.
-
公开(公告)号：US20230073461A1
公开(公告)日：2023-03-09
申请号：US17699035
申请日：2022-03-18
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
IPC: A61K39/12 , A61K31/7105 , A61K31/7115 , A61K31/712 , A61K9/127 , A61K9/51 , A61P31/14 , B82Y5/00 , C12N15/11 , C12N15/67 , C12N15/88 , C12P19/34
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
Patent Agency Ranking
公开(公告)号：US11547673B1
公开(公告)日：2023-01-10
申请号：US17233396
申请日：2021-04-16
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
公开(公告)号：US20220378876A1
公开(公告)日：2022-12-01
申请号：US17763329
申请日：2020-09-22
Applicant: BioNTech SE , Tron-Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz
Inventor： Ugur Sahin , Mathias Vormehr , Jan David Beck , Mustafa Diken , Sebastian Kreiter
IPC: A61K38/20 , A61K39/39 , A61K39/395 , A61K45/06 , A61P35/00
Abstract: Tumor cells often evade an immune response, e.g., by reducing or eliminating MHC expression and/or IFN-signaling, which enables uncontrolled growth. We demonstrate herein that antibody-based immunotherapy in combination with IL2 administration is an effective therapy against such resistant tumors. Specifically, the present disclosure relates to methods of treating a subject with cancer that is at least partially resistant to an MHC-dependent T cell response comprising administering to the subject: a. a polypeptide comprising IL2 or a functional variant thereof or a polynucleotide encoding a polypeptide comprising IL2 or a functional variant thereof; and b. antibody-based immunotherapy.
-
公开(公告)号：US11504419B2
公开(公告)日：2022-11-22
申请号：US16172063
申请日：2018-10-26
Applicant: BioNTech SE , TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
Inventor： Ugur Sahin , Claudia Paret , Kirsten Vormbrock , Christian Bender , Jan Diekmann
Abstract: The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.
-
公开(公告)号：US11459395B2
公开(公告)日：2022-10-04
申请号：US17172694
申请日：2021-02-10
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil Altintas , David Satijn , Rik Rademaker , Paul Parren , Ugur Sahin , Friederike Gieseke , Alexander Muik , Christian Grunwitz , Edward Van den Brink , Dennis Verzijl
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号：US20220257783A1
公开(公告)日：2022-08-18
申请号：US17688707
申请日：2022-03-07
Applicant: BioNTech SE
Inventor： Ozlem Tureci , Ugur Sahin , Sebastian Kreiter
Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
-
-
-
-
-
-
-
-
-
Search Results
161
records
(took 0.026 seconds)
